losartan has been researched along with Stroke in 117 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 9.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients." | 9.17 | Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study. ( Hong, YH; Kwon, HM; Lee, YS; Lim, JS; Nam, H; Shin, JW, 2013) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 9.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)." | 9.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study demonstrated the clinical benefit of losartan-based therapy in hypertensive patients with left ventricular hypertrophy (LVH), mainly due to a highly significant 25% reduction in the relative risk of stroke compared with an atenolol-based regimen, for a similar reduction in blood pressure." | 9.12 | Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, G; McInnes, G, 2006) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 9.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 9.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 9.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 9.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "Losartan may be introduced within 2-7 days of mild stroke in hypertensive patients in whom significant carotid occlusive disease has been excluded without affecting global or regional CBF, or affecting GFR." | 9.11 | The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. ( Bolster, A; Hilditch, TE; Lees, KR; Nazir, FS; Overell, JR; Reid, JL, 2004) |
| "Losartan enhances the nocturnal decrease in ambulatory BP compared with that of quinapril in patients with a previous history of stroke presumably by way of the suppression of nocturnal sympathetic nervous activity." | 9.10 | Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor. ( Fujiwara, N; Kato, T; Konta, Y; Metoki, N; Okuguchi, T; Okumura, K; Osanai, T, 2002) |
| "These data suggest that losartan is superior to atenolol for treatment of patients with isolated systolic hypertension and ECG-LVH." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "Relevant randomized clinical trials and review articles were identified through a MEDLINE search of English-language articles published between 1990 and 2006 using the search terms losartan, atenolol, LIFE, hypertension, and LVH." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress." | 8.83 | Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006) |
| " Angiotensin II (AII) may be intimately involved in the pathogenesis of systolic hypertension through multiple mechanisms, including decreasing the elastin content and increasing the collagen content of the arterial wall, thickening and fibrotic remodelling of the vascular intima, and proliferating smooth muscle cells in the arterial wall, resulting in increased thickness, stiffening, and partial loss of contractility." | 8.82 | Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. ( Volpe, M, 2005) |
| " Considering the causal relationship between hypertension and AD and that targeting cerebrovascular pathology with ARBs does not necessarily require their systemic effects, we tested intranasal losartan in the rat model of chronic hypertension (spontaneously hypertensive stroke-prone rats, SHRSP)." | 7.91 | Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats. ( Beer-Hammer, S; Buadze, M; Danielyan, L; Davtyan, T; Drews, HJ; Frey, WH; Gleiter, CH; Kabisch, D; Lourhmati, A; Petschak, S; Schwab, M; Verleysdonk, S; Yenkoyan, K, 2019) |
| "We assessed the ability of poststroke losartan and captopril treatment to attenuate hematoma expansion and plasma extravasation after intracerebral hemorrhagic stroke in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp)." | 7.88 | Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure. ( Negandhi, A; Smeda, JS; Stuckless, J; Watson, D, 2018) |
| "The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke-prone (SHRSP) rats against the risk of stroke." | 7.83 | Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats. ( He, D; Lin, J; Zhang, L, 2016) |
| "The ability of captopril and losartan treatment to restore cerebral blood flow (CBF) autoregulation after intracerebral hemorrhagic stroke (HS) was assessed in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp)." | 7.77 | The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. ( Daneshtalab, N; Smeda, JS, 2011) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "We assessed the ability of poststroke captopril and losartan treatment to reverse myogenic and endothelial dysfunction in the middle cerebral arteries of Kyoto-Wistar stroke-prone spontaneously hypertensive rats (SHRsp) that developed intracerebral hemorrhagic stroke." | 7.74 | Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp. ( McGuire, JJ; Smeda, JS, 2007) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study was performed to investigate the relationship between blood pressure (BP) and development of stroke or myocardial infarction (MI) in Japanese hypertensive patients." | 7.74 | Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 7.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "From a Canadian societal perspective, losartan appears to be a cost-effective alternative to atenolol in patients with hypertension and LVH." | 7.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 7.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| "Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk." | 6.73 | Impact of losartan on stroke risk in hypertensive patients in primary care. ( Bestehorn, K; Wahle, K, 2007) |
| "It is indicated for the treatment of hypertension (including as initial therapy in severe hypertension) and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy (LVH)." | 6.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group." | 6.44 | Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. ( Høieggen, A; Kizer, JR; Kjeldsen, SE; Lyle, PA; Oparil, S; Os, I, 2007) |
| "Losartan (Cozaar) is an angiotensin AT1 receptor antagonist." | 6.43 | Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Moen, MD; Wagstaff, AJ, 2005) |
| "Prehypertension has been associated with adverse cerebrovascular events and brain damage." | 5.40 | Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. ( He, DH; Lin, JX; Lin, LM; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2014) |
| "Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface." | 5.31 | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001) |
| "Both losartan and enalapril decreased cerebral edema to baseline levels." | 5.31 | Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. ( Blezer, EL; Joles, JA; Koomans, HA; Nicolay, K, 2001) |
| "8 years' losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke." | 5.20 | Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. ( Bang, CN; Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Hille, DA; Nieminen, MS; Palmieri, V; Papademetriou, V; Roman, MJ; Wachtell, K, 2015) |
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 5.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "Carotid endarterectomy and medical therapy (aspirin) were shown superior to medical therapy alone for asymptomatic (≥ 60%) carotid stenosis." | 5.20 | Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study. ( Boytsov, S; Deev, A; Dupik, N; Kolos, I; Loukianov, M, 2015) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.17 | Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. ( Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Lund, BP; Nieminen, MS; Okin, PM; Wachtell, K, 2013) |
| "This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients." | 5.17 | Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study. ( Hong, YH; Kwon, HM; Lee, YS; Lim, JS; Nam, H; Shin, JW, 2013) |
| "8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.15 | In-treatment stroke volume predicts cardiovascular risk in hypertension. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Lønnebakken, MT; Wachtell, K, 2011) |
| "A total of 937 hypertensive patients with ECG LVH were studied by echocardiography in the Losartan Intervention For Endpoint reduction in hypertension study." | 5.14 | Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. ( Boman, K; Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Olofsson, M; Papademetriou, V; Wachtell, K, 2009) |
| " These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women." | 5.13 | Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Franco, V; Gerdts, E; Hille, DA; Kjeldsen, SE; Lyle, PA; Manhem, K; Okin, PM; Oparil, S; Os, I, 2008) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, doubleblind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease (CVD)-related morbidity and mortality in 9193 patients with hypertension and left-ventricular hypertrophy (LVH)." | 5.12 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. ( Atthobari, J; Boersma, C; Carides, GW; Postma, MJ; Voors, AA, 2007) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study demonstrated the clinical benefit of losartan-based therapy in hypertensive patients with left ventricular hypertrophy (LVH), mainly due to a highly significant 25% reduction in the relative risk of stroke compared with an atenolol-based regimen, for a similar reduction in blood pressure." | 5.12 | Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, G; McInnes, G, 2006) |
| "The Losartan Intervention For End point reduction in hypertension (LIFE) study showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke, and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; De Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "We studied the impact of smoking in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which showed superiority of losartan over atenolol for reduction of composite risk of cardiovascular death, stroke and myocardial infarction in hypertensives with left ventricular hypertrophy." | 5.11 | Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. ( Beevers, G; Brady, WE; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Reims, HM; Wedel, H, 2004) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH)." | 5.11 | The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan- vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Burke, TA; Carides, GW; Dahlöf, B; Devereux, RB; Diener, HC; Edelman, JM; Krobot, K, 2004) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 5.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "Losartan may be introduced within 2-7 days of mild stroke in hypertensive patients in whom significant carotid occlusive disease has been excluded without affecting global or regional CBF, or affecting GFR." | 5.11 | The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke. ( Bolster, A; Hilditch, TE; Lees, KR; Nazir, FS; Overell, JR; Reid, JL, 2004) |
| "Losartan enhances the nocturnal decrease in ambulatory BP compared with that of quinapril in patients with a previous history of stroke presumably by way of the suppression of nocturnal sympathetic nervous activity." | 5.10 | Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor. ( Fujiwara, N; Kato, T; Konta, Y; Metoki, N; Okuguchi, T; Okumura, K; Osanai, T, 2002) |
| "These data suggest that losartan is superior to atenolol for treatment of patients with isolated systolic hypertension and ECG-LVH." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "Relevant randomized clinical trials and review articles were identified through a MEDLINE search of English-language articles published between 1990 and 2006 using the search terms losartan, atenolol, LIFE, hypertension, and LVH." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "A PubMed/MEDLINE search of English-language articles (1990 to February 2006) with the terms angiotensin II antagonists or AIIAs or angiotensin receptor blockers or losartan or atenolol or beta blocker and terms including, but not limited to, atherosclerosis, left ventricular hypertrophy, carotid artery hypertrophy, fatty streaks, atrial fibrillation, arrhythmias, endothelial function, myocyte hypertrophy, myocardial fibrosis, platelet aggregation, tissue factor, plasminogen activator inhibitor-1, PAI-1, anti-inflammatory, uric acid, or oxidative stress." | 4.83 | Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. ( Díez, J, 2006) |
| " Angiotensin II (AII) may be intimately involved in the pathogenesis of systolic hypertension through multiple mechanisms, including decreasing the elastin content and increasing the collagen content of the arterial wall, thickening and fibrotic remodelling of the vascular intima, and proliferating smooth muscle cells in the arterial wall, resulting in increased thickness, stiffening, and partial loss of contractility." | 4.82 | Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. ( Volpe, M, 2005) |
| " The search terms were stroke, epidemiology, economic impact, disability, quality of life, hypertension, drug therapy, and angiotensin II-receptor antagonists." | 4.82 | Prevention and treatment of stroke in patients with hypertension. ( Mancia, G, 2004) |
| " Considering the causal relationship between hypertension and AD and that targeting cerebrovascular pathology with ARBs does not necessarily require their systemic effects, we tested intranasal losartan in the rat model of chronic hypertension (spontaneously hypertensive stroke-prone rats, SHRSP)." | 3.91 | Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats. ( Beer-Hammer, S; Buadze, M; Danielyan, L; Davtyan, T; Drews, HJ; Frey, WH; Gleiter, CH; Kabisch, D; Lourhmati, A; Petschak, S; Schwab, M; Verleysdonk, S; Yenkoyan, K, 2019) |
| "We assessed the ability of poststroke losartan and captopril treatment to attenuate hematoma expansion and plasma extravasation after intracerebral hemorrhagic stroke in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp)." | 3.88 | Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure. ( Negandhi, A; Smeda, JS; Stuckless, J; Watson, D, 2018) |
| "The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke-prone (SHRSP) rats against the risk of stroke." | 3.83 | Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats. ( He, D; Lin, J; Zhang, L, 2016) |
| "Risk of incident stroke was examined in relation to abnormal PTFV1 on a baseline ECG in 7778 hypertensive patients with ECG left ventricular hypertrophy, no history of atrial fibrillation, in sinus rhythm on their baseline ECG with no incident atrial fibrillation during follow-up, who were randomly assigned to losartan-based or atenolol-based treatment." | 3.83 | Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy. ( Devereux, RB; Kamel, H; Kjeldsen, SE; Okin, PM, 2016) |
| "Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension." | 3.79 | Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013) |
| " Methods Baseline and follow-up clinical and echocardiographic parameters were assessed in 939 hypertensive patients with electrocardiogram (ECG) LVH participating in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) echocardiography substudy (66±7 years; 42% women; 11% with diabetes) who did not have aortic or mitral valve stenosis or prosthesis." | 3.79 | Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study. ( Boman, K; Casalnuovo, G; Dahlöf, B; De Marco, M; de Simone, G; Devereux, RB; Gerdts, E; Kizer, JR; Migliore, T; Olsen, MH; Wachtell, K, 2013) |
| "The ability of captopril and losartan treatment to restore cerebral blood flow (CBF) autoregulation after intracerebral hemorrhagic stroke (HS) was assessed in Kyoto-Wistar stroke-prone hypertensive rats (SHRsp)." | 3.77 | The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. ( Daneshtalab, N; Smeda, JS, 2011) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "A total of 500 outpatients with primary AH and risk factors including the risk of stroke received Hyzaar (losartan 50/100 mg and hydrochlorthiaside 12." | 3.75 | [Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program]. ( Bubnova, MG; Oganov, RG, 2009) |
| "We assessed the ability of poststroke captopril and losartan treatment to reverse myogenic and endothelial dysfunction in the middle cerebral arteries of Kyoto-Wistar stroke-prone spontaneously hypertensive rats (SHRsp) that developed intracerebral hemorrhagic stroke." | 3.74 | Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp. ( McGuire, JJ; Smeda, JS, 2007) |
| "The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study was performed to investigate the relationship between blood pressure (BP) and development of stroke or myocardial infarction (MI) in Japanese hypertensive patients." | 3.74 | Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. ( Fujita, T; Ito, S; Naritomi, H; Ogihara, T; Shimada, K; Shimamoto, K; Tanaka, H; Yoshiike, N, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy." | 3.73 | Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Lyle, PA; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wedel, H, 2005) |
| "From a Canadian societal perspective, losartan appears to be a cost-effective alternative to atenolol in patients with hypertension and LVH." | 3.73 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. ( Anis, AH; Brisson, M; Nosyk, B; Singh, S; Sun, H; Woolcott, J, 2006) |
| "The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) was a double-masked, randomized trial of losartan versus atenolol in 9193 patients with essential hypertension and left ventricular hypertrophy (LVH) ascertained by electrocardiography." | 3.73 | Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. ( Burke, TA; Carides, GW; Dahlöf, B; Dasbach, EJ; Jönsson, B; Lindholm, LH, 2005) |
| " The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study provides additional data to support the use of the ACE inhibitors to lower the risk of stroke among patients with hypertension and vascular diseases." | 3.72 | New strategies for prevention of ischemic stroke: the LIFE study. ( Adams, HP, 2003) |
| "The LIFE study ("Losartan Intervention For Endpoint reduction in hypertension study") demonstrated a significant cardiovascular protection by an angiotensin AT1 receptor antagonist, losartan, in hypertensive patients with left ventricular hypertrophy." | 3.71 | [Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan]. ( Scheen, AJ, 2002) |
| "Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk." | 2.73 | Impact of losartan on stroke risk in hypertensive patients in primary care. ( Bestehorn, K; Wahle, K, 2007) |
| "Risk of stroke was increased for the first 30 days (HR 14." | 2.71 | Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. ( Dickstein, K; Lehto, M; Nieminen, MS; Snapinn, S; Swedberg, K, 2005) |
| "Prevention of epilepsy is a great unmet need." | 2.66 | Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? ( Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020) |
| " However, pharmacologic and dosing differences exist among the various ARBs, and these differences can potentially influence their individual effectiveness." | 2.46 | Comparing angiotensin II receptor blockers on benefits beyond blood pressure. ( Siragy, HM, 2010) |
| "It is indicated for the treatment of hypertension (including as initial therapy in severe hypertension) and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy (LVH)." | 2.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group." | 2.44 | Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. ( Høieggen, A; Kizer, JR; Kjeldsen, SE; Lyle, PA; Oparil, S; Os, I, 2007) |
| "However, stroke is a highly preventable disease in the majority of patients." | 2.43 | Strategies for primary and secondary stroke prevention. ( Brass, LM, 2006) |
| "Losartan is a competitive antagonist that causes a parallel rightward shift of the concentration-contractile response curve to angiotensin-II, while E 3174 is a noncompetitive "insurmountable" antagonist of angiotensin-II." | 2.43 | Clinical pharmacokinetics of losartan. ( Gehr, TW; Ghosh, S; Sica, DA, 2005) |
| "Losartan (Cozaar) is an angiotensin AT1 receptor antagonist." | 2.43 | Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Moen, MD; Wagstaff, AJ, 2005) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| "As stroke is characterised by vascular remodelling and dysfunction and by effects on the cerebral circulation, selecting an agent that has a direct vascular protective effect beyond blood pressure control may be desirable." | 2.42 | Stroke prevention: is it possible? If so, which antihypertensive agent should be used? ( Kim, S, 2003) |
| "Prehypertension has been associated with adverse cerebrovascular events and brain damage." | 1.40 | Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. ( He, DH; Lin, JX; Lin, LM; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2014) |
| "Both losartan and enalapril decreased cerebral edema to baseline levels." | 1.31 | Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats. ( Blezer, EL; Joles, JA; Koomans, HA; Nicolay, K, 2001) |
| "Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface." | 1.31 | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 86 (73.50) | 29.6817 |
| 2010's | 29 (24.79) | 24.3611 |
| 2020's | 2 (1.71) | 2.80 |
| Authors | Studies |
|---|---|
| Klein, P | 1 |
| Friedman, A | 1 |
| Hameed, MQ | 1 |
| Kaminski, RM | 1 |
| Bar-Klein, G | 1 |
| Klitgaard, H | 1 |
| Koepp, M | 1 |
| Jozwiak, S | 1 |
| Prince, DA | 1 |
| Rotenberg, A | 1 |
| Twyman, R | 1 |
| Vezzani, A | 1 |
| Wong, M | 1 |
| Löscher, W | 1 |
| Marshall, M | 1 |
| Culman, J | 1 |
| Jacob, T | 1 |
| Schuster, SO | 1 |
| Brolund-Spaether, K | 1 |
| Brolund, L | 1 |
| Cascorbi, I | 1 |
| Zhao, Y | 1 |
| Gohlke, P | 1 |
| Smeda, JS | 3 |
| Watson, D | 1 |
| Stuckless, J | 1 |
| Negandhi, A | 1 |
| Diestro, JDB | 1 |
| Sedano, LSP | 1 |
| Reyes, NGD | 1 |
| San Jose, MCZ | 1 |
| Drews, HJ | 1 |
| Yenkoyan, K | 1 |
| Lourhmati, A | 1 |
| Buadze, M | 1 |
| Kabisch, D | 1 |
| Verleysdonk, S | 1 |
| Petschak, S | 1 |
| Beer-Hammer, S | 1 |
| Davtyan, T | 1 |
| Frey, WH | 1 |
| Gleiter, CH | 1 |
| Schwab, M | 1 |
| Danielyan, L | 1 |
| Kolos, I | 1 |
| Loukianov, M | 1 |
| Dupik, N | 1 |
| Boytsov, S | 1 |
| Deev, A | 1 |
| Antoniou, T | 1 |
| Camacho, X | 1 |
| Yao, Z | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Kwon, HM | 1 |
| Shin, JW | 1 |
| Lim, JS | 1 |
| Hong, YH | 1 |
| Lee, YS | 1 |
| Nam, H | 1 |
| He, DH | 1 |
| Zhang, LM | 1 |
| Lin, LM | 1 |
| Ning, RB | 1 |
| Wang, HJ | 1 |
| Xu, CS | 1 |
| Lin, JX | 1 |
| Bang, CN | 2 |
| Gerdts, E | 11 |
| Aurigemma, GP | 2 |
| Boman, K | 9 |
| de Simone, G | 4 |
| Dahlöf, B | 25 |
| Køber, L | 1 |
| Wachtell, K | 17 |
| Devereux, RB | 27 |
| Nakane, H | 1 |
| Kamouchi, M | 1 |
| Hata, J | 1 |
| Ibayashi, S | 1 |
| Kusuda, K | 1 |
| Omae, T | 1 |
| Nagao, T | 1 |
| Ago, T | 1 |
| Kitazono, T | 1 |
| Katsuki, M | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Sunagawa, K | 1 |
| Vishram, JK | 1 |
| Ibsen, H | 13 |
| Kjeldsen, SE | 17 |
| Lindholm, LH | 10 |
| Mancia, G | 3 |
| Okin, PM | 5 |
| Rothwell, PM | 1 |
| Olsen, MH | 10 |
| Roman, MJ | 1 |
| Palmieri, V | 2 |
| Nieminen, MS | 13 |
| Papademetriou, V | 4 |
| Hille, DA | 4 |
| Zhang, L | 1 |
| He, D | 1 |
| Lin, J | 1 |
| Wald, NJ | 2 |
| Luteijn, JM | 2 |
| Morris, JK | 2 |
| Taylor, D | 1 |
| Oppenheimer, P | 1 |
| Kamel, H | 1 |
| Mancusi, C | 1 |
| Midtbø, H | 1 |
| Lønnebakken, MT | 2 |
| Zahid, HM | 1 |
| Ferdaus, MZ | 1 |
| Ohara, H | 1 |
| Isomura, M | 1 |
| Nabika, T | 1 |
| Shimada, K | 2 |
| Fujita, T | 2 |
| Ito, S | 2 |
| Naritomi, H | 3 |
| Ogihara, T | 2 |
| Shimamoto, K | 2 |
| Tanaka, H | 2 |
| Yoshiike, N | 2 |
| Olofsson, M | 1 |
| Keating, GM | 1 |
| Bubnova, MG | 1 |
| Oganov, RG | 1 |
| Stålhammar, J | 1 |
| Hasvold, P | 1 |
| Bodegard, J | 1 |
| Olsson, U | 1 |
| Russell, D | 1 |
| Rokkedal, JE | 1 |
| Larstorp, AC | 1 |
| Siragy, HM | 1 |
| Daneshtalab, N | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Parving, HH | 1 |
| Lambers Heerspink, HJ | 1 |
| Lund, BP | 1 |
| Rehman, A | 1 |
| Leibowitz, A | 1 |
| Yamamoto, N | 1 |
| Rautureau, Y | 1 |
| Paradis, P | 1 |
| Schiffrin, EL | 1 |
| De Marco, M | 1 |
| Casalnuovo, G | 1 |
| Migliore, T | 1 |
| Kizer, JR | 4 |
| Böhm, S | 1 |
| Julius, S | 9 |
| Aurup, P | 1 |
| Edelman, J | 1 |
| Beevers, G | 6 |
| de Faire, U | 7 |
| Fyhrquist, F | 8 |
| Kristianson, K | 6 |
| Lederballe-Pedersen, O | 7 |
| Omvik, P | 8 |
| Oparil, S | 9 |
| Snapinn, S | 2 |
| Wedel, H | 6 |
| Okuguchi, T | 1 |
| Osanai, T | 1 |
| Fujiwara, N | 1 |
| Kato, T | 1 |
| Metoki, N | 1 |
| Konta, Y | 1 |
| Okumura, K | 1 |
| Karpov, IuA | 1 |
| Adams, HP | 1 |
| Weder, AB | 1 |
| Fleming, T | 1 |
| Borer, J | 1 |
| Armstrong, PW | 1 |
| Pfeffer, M | 1 |
| Messerli, FH | 2 |
| Grossman, E | 1 |
| Fournier, A | 3 |
| Oprisiu, R | 1 |
| Andrejak, M | 1 |
| Fernandez, L | 1 |
| Achard, JM | 2 |
| Danchin, N | 1 |
| Baumgart, P | 2 |
| Diener, HC | 2 |
| Kim, S | 1 |
| Stöllberger, C | 1 |
| Slany, J | 1 |
| Brainin, M | 1 |
| Finsterer, J | 1 |
| Bramlage, P | 1 |
| Wittchen, HU | 1 |
| Pittrow, D | 1 |
| Dikow, R | 1 |
| Kirch, W | 1 |
| Lehnert, H | 1 |
| Ritz, E | 1 |
| Aronow, WS | 1 |
| Frishman, WH | 1 |
| Burke, TA | 3 |
| Krobot, K | 1 |
| Carides, GW | 3 |
| Edelman, JM | 3 |
| Nazir, FS | 1 |
| Overell, JR | 1 |
| Bolster, A | 1 |
| Hilditch, TE | 1 |
| Reid, JL | 1 |
| Lees, KR | 1 |
| Reims, HM | 3 |
| Brady, WE | 2 |
| Moriwaki, H | 1 |
| Uno, H | 1 |
| Nagakane, Y | 1 |
| Hayashida, K | 1 |
| Miyashita, K | 1 |
| Tatsuno, I | 1 |
| Kumagai, H | 1 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Saruta, T | 1 |
| Tomiyama, H | 1 |
| Takata, Y | 1 |
| Yamashina, A | 1 |
| Tuxen, C | 1 |
| Fossum, E | 2 |
| Bang, LE | 1 |
| Hall, C | 1 |
| Rokkedal, J | 1 |
| Hildebrandt, P | 1 |
| Borch-Johnsen, K | 1 |
| Mogensen, CE | 1 |
| Wan, Y | 2 |
| Volpe, M | 1 |
| Forder, JP | 1 |
| Munzenmaier, DH | 1 |
| Greene, AS | 1 |
| Ferrario, CM | 1 |
| Chrysant, SG | 2 |
| Snapinn, SM | 3 |
| Harris, KE | 2 |
| Lehto, M | 2 |
| Dickstein, K | 1 |
| Swedberg, K | 1 |
| Hornestam, B | 1 |
| Bourassa, MG | 1 |
| Lyle, PA | 5 |
| Grassi, G | 1 |
| Quarti, F | 1 |
| Jönsson, B | 1 |
| Dasbach, EJ | 1 |
| Safar, ME | 1 |
| O'Rourke, MF | 1 |
| Sica, DA | 1 |
| Gehr, TW | 1 |
| Ghosh, S | 1 |
| Franklin, SS | 1 |
| McInnes, G | 1 |
| Carides, G | 1 |
| Moen, MD | 1 |
| Wagstaff, AJ | 1 |
| Loh, KP | 1 |
| Low, LS | 1 |
| Wong, WH | 1 |
| Zhou, S | 1 |
| Huang, SH | 1 |
| De Silva, R | 1 |
| Duan, W | 1 |
| Chou, WH | 1 |
| Zhu, YZ | 1 |
| Høieggen, A | 3 |
| Chrysant, GS | 1 |
| Anis, AH | 1 |
| Sun, H | 1 |
| Singh, S | 1 |
| Woolcott, J | 1 |
| Nosyk, B | 1 |
| Brisson, M | 1 |
| Krauser, DG | 1 |
| Díez, J | 1 |
| Otani, L | 1 |
| Yasumatsu, T | 1 |
| Murakami, M | 1 |
| Hayashi, A | 1 |
| Kimoto, K | 1 |
| Murakami, T | 1 |
| Hiwada, K | 1 |
| Otterstad, JE | 1 |
| Oikarinen, L | 1 |
| Varughese, GI | 1 |
| Tahrani, AA | 1 |
| McGuire, JJ | 1 |
| Brass, LM | 1 |
| Bestehorn, K | 1 |
| Wahle, K | 1 |
| Boersma, C | 1 |
| Atthobari, J | 1 |
| Voors, AA | 1 |
| Postma, MJ | 1 |
| Os, I | 3 |
| Smebye, ML | 1 |
| Iversen, EK | 1 |
| Flaa, A | 1 |
| Chattopadhyay, A | 1 |
| Victor, RG | 1 |
| Franco, V | 1 |
| Manhem, K | 1 |
| Arai, T | 2 |
| Yasuda, Y | 2 |
| Takaya, T | 2 |
| Toshima, S | 2 |
| Kashiki, Y | 2 |
| Yoshimii, N | 1 |
| Fujiwara, H | 2 |
| Yoshimi, N | 1 |
| Blezer, EL | 1 |
| Nicolay, K | 1 |
| Koomans, HA | 1 |
| Joles, JA | 1 |
| Jiménez, AM | 1 |
| Montón, M | 1 |
| García, R | 1 |
| Núñez, A | 1 |
| Gómez, J | 1 |
| Rico, L | 1 |
| García-Colis, E | 1 |
| de Miguel, LS | 1 |
| Arriero, MM | 1 |
| Cabestrero, F | 1 |
| Farré, J | 1 |
| Casado, S | 1 |
| López-Farré, A | 1 |
| Dalmay, F | 1 |
| Mazouz, H | 1 |
| Allard, J | 1 |
| Pesteil, F | 1 |
| Einecke, D | 1 |
| Scheen, AJ | 1 |
| Montastruc, JL | 1 |
| Pathak, A | 1 |
| Lapeyre-Mestre, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis[NCT00805311] | Phase 4 | 400 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Due to the clear advantage of carotid endarterectomy) | ||
| Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients[NCT01830517] | Phase 4 | 84 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease[NCT02373241] | Phase 2 | 1 participants (Actual) | Interventional | 2015-04-30 | Terminated (stopped due to Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.) | ||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Outcome 1a. Document the rate of acceptance (quantitative) and reasons for acceptance/rejection (qualitative) in a randomized trial of trial of losartan for SCD patients with abnormal nocturnal blood pressures.~Outcome 1b. Identify the adherence rate to losartan during a randomized three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure.~Outcome 1c. Determine the adherence rate to study procedures among participants enrolled in a three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure." (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
As a feasibility trial, the effect of losartan on lowering nocturnal hypertension will be monitored to identify the difference in nocturnal BP improvement between the two treatment arms, and within group standard deviation of BP (NCT02373241)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Blood Pressure Management | 1 |
We will prospectively evaluate the incidence of hypertension (Clinic BP in pts >5yrs and ABPM in pts >10 yrs) and role of blood and urine biomarkers (pts >5ys) among participants with HbSS or SB0 thalassemia (expected cohort n=200) over 5 yrs. We identified 20 participants (34%) with incident hypertension but randomized one to the study. The study was terminated as the eGFR was determined not to be a reliable endpoint in pediatric sickle cell. (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
25 reviews available for losartan and Stroke
| Article | Year |
|---|---|
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Cef | 2020 |
Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinati | 2009 |
Comparing angiotensin II receptor blockers on benefits beyond blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Dis | 2010 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
Stroke prevention: is it possible? If so, which antihypertensive agent should be used?
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Treatment of hypertension and prevention of ischemic stroke.
Topics: Algorithms; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Diltiazem; Humans; Hyperte | 2004 |
[Hyperuricemia in hypertension].
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Diet, Sodium-Restricte | 2004 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
[Management of hypertensive patients with cardiovascular damage].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
Prevention and treatment of stroke in patients with hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Anticoagulants; Antihypertensive Agents; Costs and | 2004 |
Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Clinical Trials as | 2005 |
The role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartan.
Topics: Angiotensin II; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Losartan; S | 2004 |
Stroke prevention with losartan in the context of other antihypertensive drugs.
Topics: Angiotensin II; Antihypertensive Agents; Clinical Trials as Topic; Humans; Losartan; Stroke | 2004 |
Hypertension, antihypertensive treatment and stroke prevention.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Clinical Trials as Topic; Humans; | 2005 |
Clinical pharmacokinetics of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Humans; Hy | 2005 |
Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Hypertension; Hypertrophy, Left Ventricular; Losart | 2005 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2006 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Endothelium, Vascular; Fibrosis; H | 2006 |
[LIFE].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Double-Bl | 2006 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
Strategies for primary and secondary stroke prevention.
Topics: Antihypertensive Agents; Clopidogrel; Humans; Losartan; Platelet Aggregation Inhibitors; Randomized | 2006 |
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Humans; | 2007 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
33 trials available for losartan and Stroke
| Article | Year |
|---|---|
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endartere | 2015 |
Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2013 |
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2015 |
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Electrocardiography; Fem | 2017 |
The importance of home blood pressure measurement for preventing stroke and cardiovascular disease in hypertensive patients: a sub-analysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospectiv
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2008 |
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Exercise; Fe | 2009 |
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
Topics: Aged; Blood Pressure; Cardiovascular System; Echocardiography; Endocardium; Female; Follow-Up Studie | 2010 |
In-treatment stroke volume predicts cardiovascular risk in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Follo | 2011 |
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Doub | 2013 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effect of losartan on nocturnal blood pressure in patients with stroke: comparison with angiotensin converting enzyme inhibitor.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Circadian Rhythm; Cr | 2002 |
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; European Union; Female; Humans; Hyperten | 2004 |
The effect of losartan on global and focal cerebral perfusion and on renal function in hypertensives in mild early ischaemic stroke.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Cerebrovascular Ci | 2004 |
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Atenolol; Female; Humans; Hypert | 2004 |
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hyp | 2004 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Captopr | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Topics: Aged; Analysis of Variance; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Humans; | 2004 |
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epi | 2005 |
Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Cost-Benefit Analysis; Female; Fol | 2006 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Echocardiograph | 2007 |
Impact of losartan on stroke risk in hypertensive patients in primary care.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Dr | 2007 |
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analy | 2007 |
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antih | 2007 |
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Female; | 2008 |
Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and symptomless dysphagia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
Angiotensin II receptor antagonists cannot prevent symptomless dysphagia in hypertensive bedridden older patients with stroke.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bed Rest; Case-C | 2000 |
59 other studies available for losartan and Stroke
| Article | Year |
|---|---|
COVID and the brain: researchers zero in on how damage occurs.
Topics: Animals; Antibodies, Viral; Astrocytes; Autoantibodies; Autopsy; Brain; Capillaries; COVID-19; Crice | 2021 |
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2017 |
Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2018 |
Hemilingual Angioedema after Thrombolysis in a Patient on an Angiotensin II Receptor Blocker.
Topics: Administration, Intravenous; Angioedema; Angiotensin II Type 1 Receptor Blockers; Fibrinolytic Agent | 2019 |
Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats.
Topics: Administration, Intranasal; Amyloid beta-Peptides; Angiotensin II Type 1 Receptor Blockers; Animals; | 2019 |
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo | 2013 |
Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats.
Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Apoptosis; Blood Pressure; Brain; Hypertension; Lo | 2014 |
Decreased proportion of Foxp3+ CD4+ regulatory T cells contributes to the development of hypertension in genetically hypertensive rats.
Topics: Animals; Blood Pressure; Cardiomegaly; Forkhead Transcription Factors; Hypertension; Interleukin-2; | 2015 |
Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Animals; Blood Pressure; Gene Expression Regulation; Humans; Hypertension; Losartan; Mal | 2016 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort St | 2016 |
Starting the polypill: the use of a single age cut-off in males and females.
Topics: Adult; Age Factors; Aged; Cardiovascular Agents; Drug Combinations; Female; Humans; Hydrochlorothiaz | 2017 |
Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Atrial Function, Left; Electrocardiography; Fe | 2016 |
Effect of p22phox depletion on sympathetic regulation of blood pressure in SHRSP: evaluation in a new congenic strain.
Topics: Acetophenones; Animals; Animals, Congenic; Antioxidants; Blood Pressure; Brain Stem; Cold Temperatur | 2016 |
[Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program].
Topics: Aged; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle A | 2009 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Electrocardiography; Female; Follow-Up S | 2011 |
The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2011 |
Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Collagen; Disease Models, A | 2012 |
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Calcinosis; Cardiomyopathies; Echocardiography; Female; Humans; Hypertensio | 2013 |
[Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Dose-R | 2002 |
[Preventing stroke. Which antihypertensive drugs can do it better?].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Losartan; Randomized Controlled Trials as T | 2002 |
New strategies for prevention of ischemic stroke: the LIFE study.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol | 2003 |
Best bang for the buck?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Food and Drug Administration: Cardiovascular and Renal Drugs Advisory Committee, 98th meeting, January 6th-7th, 2003.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atenolol; Ca | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 2003 |
[Suboptimal results of Optimaal: treatment with ACE inhibitors remains the preferred therapy in patients with left ventricular dysfunction after acute myocardial infarct]].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Death; Female; Humans; Length of Stay; | 2002 |
The LIFE study: the straw that should break the camel's back.
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; My | 2003 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; F | 2003 |
[To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Humans; Hypertension; Los | 2003 |
[Microalbuminuria is an early marker for increased morbidity and mortality].
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom | 2003 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2004 |
[When compliance doesn't work out. Calculate the risk of stroke for hypertensive patients!].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Causality; Clinical Trials as Topic; | 2004 |
Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Infarction; Cerebrovascular Circulation; | 2005 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2005 |
[Utilizing progress in modern antihypertensive therapy. Treating hypertension effectively from the beginning].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as | 2005 |
[A suitable antihypertensive drug of significance. Protection of heart, brain and kidney is decisive].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Clinical Tria | 2005 |
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Bli | 2005 |
Pulse pressure and antihypertensive agents.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
A comparison study of cerebral protection using Ginkgo biloba extract and Losartan on stroked rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protei | 2006 |
A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Cohort Studies | 2006 |
Reduction of salt sensitivity in stroke-prone spontaneously hypertensive rats administered an AT1 receptor antagonist during suckling.
Topics: Albuminuria; Aldosterone; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; An | 2006 |
[Plus point -- risk reduction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2006 |
Treating hypertension in older people: Practical implications of achieving targets.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; European Union; Geriatrics; Humans; Hypertension; | 2006 |
Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp.
Topics: Animals; Antihypertensive Agents; Captopril; Cerebrovascular Circulation; Endothelium, Vascular; Los | 2007 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Femal | 2008 |
Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Brain Edema; Drug Admini | 2001 |
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents | 2001 |
Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; B | 2001 |
[Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
Topics: Antihypertensive Agents; Atenolol; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pr | 2002 |
[Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan].
Topics: Aged; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Endpoint Determination; Female; H | 2002 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Antihypertensive Agents; Atenolol; Endpoint Determination; Humans; Losartan; Stroke; Treatment Outco | 2002 |